Iván González: The ESPAC4 study reveals promising results in treating pancreatic adenocarcinoma
Iván González, Medical Oncologist at the Comprehensive Oncology Center of the Hospital Ángeles Puebla, shared a post on X about a recent paper by Daniel Palmer et al. published in Journal of Clinical Oncology:
“The ESPAC4 study reveals promising results in treating pancreatic adenocarcinoma, highlighting the impact of GemCap as an adjuvant therapy compared to gemcitabine. These findings provide valuable insights to optimize therapeutic strategies, especially in specific patient subgroups.
Overall survival (OS):
- Gemcitabine: 28.4 months.
- GemCap: 31.6 months (HR 0.83; P = 0.031).
Key findings:
- R0 patients: GemCap improved OS to 49.9 months vs. 32.2 months with gemcitabine (HR 0.63; P = 0.002).
- Lymph node-negative patients: 5-year OS of 59% with GemCap vs. 53% with gemcitabine (HR 0.63; P = 0.04).
GemCap is reaffirmed as the standard treatment for patients ineligible for mFOLFIRINOX but also demonstrates superior efficacy in subgroups such as R0 patients and those without lymph node involvement.”
“Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial”
Authors: Daniel Palmer, Richard Jackson, Christoph Springfeld, Markus Büchler, John Neoptolemos et al.
More posts featuring Iván González.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023